WhaleCreep
Home › Funds › Tri Locum Partners LP › Q2 2025

Tri Locum Partners LP 13F holdings, Q2 2025

Holdings as of June 30, 2025 · filings on SEC EDGAR · latest filing →

Tri Locum Partners LP disclosed 23 US equity positions worth $329.5m in its Q2 2025 13F filing. The largest position was TEVA at 10.4% of the reported book, followed by MDGL and ALNY. Against the Q1 2025 filing, it opened 9 new positions, added to 11 and reduced 2 among the top 23 holdings.

← Q1 2025 · Q3 2025 →

What did Tri Locum Partners LP own in Q2 2025? Top 23 positions

#StockSectorWeightValueSharesΔ sharesvs Q1 2025
1 TEVA TEVA PHARMACEUTICAL INDS LTD Healthcare 10.4%$34.3m2,046,846 93% added
2 MDGL MADRIGAL PHARMACEUTICALS INC Healthcare 9.0%$29.6m97,765 158% added
3 ALNY ALNYLAM PHARMACEUTICALS INC Healthcare 8.9%$29.2m89,525 – new
4 ARGX ARGENX SE Healthcare 8.0%$26.3m47,793 168% added
5 ASND ASCENDIS PHARMA A/S Healthcare 7.7%$25.5m147,642 357% added
6 SLNOEUR SOLENO THERAPEUTICS INC 7.3%$24.2m288,880 23% added
7 VRNA VERONA PHARMA PLC 6.2%$20.5m216,578 – new
8 INSP INSPIRE MED SYS INC Healthcare 5.9%$19.4m149,244 89% added
9 UNH UNITEDHEALTH GROUP INC Healthcare 5.7%$18.9m60,584 – new
10 AXSM AXSOME THERAPEUTICS INC Healthcare 5.0%$16.5m157,861 56% added
11 EOLS EVOLUS INC Healthcare 3.5%$11.4m1,239,031 285% added
12 ABBV ABBVIE INC Healthcare 3.1%$10.3m55,661 – new
13 VERA VERA THERAPEUTICS INC Healthcare 3.0%$9.7m413,114 175% added
14 AVADEL PHARMACEUTICALS PLC 2.7%$9.0m1,014,456 – new
15 PRAX PRAXIS PRECISION MEDICINES I Healthcare 2.5%$8.2m195,432 134% added
16 TARS TARSUS PHARMACEUTICALS INC Healthcare 2.2%$7.2m177,656 – new
17 ISRG INTUITIVE SURGICAL INC Healthcare 2.1%$7.0m12,824 – new
18 LEGN LEGEND BIOTECH CORP Healthcare 1.9%$6.1m173,260 – new
19 NUVALENT INC 1.8%$5.8m75,973 -21% reduced
20 BHVN BIOHAVEN LTD Healthcare 1.2%$3.8m271,367 – new
21 KRRO KORRO BIO INC Healthcare 1.1%$3.5m139,493 9% added
22 WGS GENEDX HOLDINGS CORP Healthcare 0.9%$3.0m32,931 -43% reduced
23 FEMY FEMASYS INC 0.0%$29.6k30,606 0% held

Weights are shares of the reported long US equity book (options excluded). Values are as filed, normalised to whole dollars. Share changes compare against the immediately preceding filing only.